INTRAVENOUS IGF 1 INFUSION IN HEAD INJURY

头部损伤时静脉注射 IGF 1

• 批准号: 6281813
• 负责人: Alfred Byron Young
• 金额: $ 3.06万
• 依托单位: UNIVERSITY OF KENTUCKY
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-12-01 至 1998-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6281813
• 关键词: brain disorder chemotherapy; clinical research; drug screening /evaluation; excitatory aminoacid; head /neck injury; human subject; human therapy evaluation; hyperglycemia; insulinlike growth factor; intravenous administration; lactic acidosis; neurologic manifestations; prognosis

Test the hypothesis that intravenous (IV) IGF-1 administration enhances brain parenchymal reorganization and thereby improves neurologic outcome. Test the hypothesis that IV IGF-1 administration decreases hyperglycemia, decreases brain lactic acidosis, and prevents secondary brain injury from acidosis. Test the hypothesis that IV IGF-1 administration prevents the catabolic sequelae to injury, preserves normal blood amino acid ratios, decreases excitotoxic amino acids presented to the brain, and thereby improves recovery.

检验静脉内（IV）IGF-1给药增强的假设 脑实质重组，从而改善神经系统结局。 检验IV IGF-1给药的假设降低了高血糖， 减少脑乳酸性酸中毒，并防止次要脑损伤 酸中毒。 检验IV IGF-1给药的假设可防止 分解代谢后遗症受伤，保留正常的血液氨基酸比， 降低兴奋性氨基酸，从而 改善恢复。